Giovanni Clemente Actis

Dr. Giovanni Clemente Actis


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GAGiovanni Clemente Actis
Giovanni Clemente Actis
Rinaldo PellicanoRinaldo Pellicano
Rinaldo Pellicano
Sharmila FagooneeSharmila Fagoonee
Sharmila Fagoonee
Davide Giuseppe RibaldoneDavide Giuseppe Ribaldone
Davide Giuseppe Ribaldone
Inflammatory bowel diseases (IBD) are characterized by chronic inflammation of the intestinal mucosa and unknown etiology. In this review, we identified three main eras in the IBD history. Between the 19th and the 20th century, the primary task had been the definition of the diagnostic criteria in order to differentiate the new entity from intestinal tuberculosis. In the 20th century, an intense and prolific therapeutic research prevailed, culminating in the introduction of biological drugs in the clinical setting. Since the beginning of the 21st century, traditional definition criteria have been challenged by holistic criteria in an effort to seek a still unattained cure. Centuries of worldwide efforts on IBD etiology and therapy search have culminated in this novel strategy.

27 March 2007 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
GAGiovanni Clemente Actis
Giovanni Clemente Actis
MFMaurizio Fadda
Maurizio Fadda
EDEzio David
Ezio David
Anna SapinoAnna Sapino
Anna Sapino
There is consistent evidence that 50% of patients with acute, steroid-resistant flare of ulcerative colitis (UC) may achieve remission and avoid colectomy if treated with cyclosporin (CsA). However, follow-up of the responders has shown that most of them relapse and need surgery shortly after the response. We compared the records of our CsA-treated patients with those of other groups in order to help clarify this matter. All patients admitted consecutively to our Unit with an attack of UC and treated with CsA between January 1991 and December 1999 were studied. Patients were begun on continuously-infused CsA at 2 mg/kg/day (1991–1996), or on NEORAL at an initial dose of 5 mg/kg/day (1996–1999). The maintenance treatment included oral CsA for 3–6 months with or without azathioprine (AZA). CsA failure was defined as a relapse requiring steroids with or without progression to colectomy; the cumulative probability of relapse/colectomy was assessed by Fisher's exact tests and Kaplan-Meier analysis. Among the patients, 39/61 (63%) initially responded. These 39 included a fatality and 4 drop-outs (unrelated to the side-effects of CsA), leaving 34 patients for the study. Of these, 61% and 35% were colectomy-free at 1 and 7 years, respectively; the corresponding figures were 80 and 60% respectively in the subset treated with AZA, but 47% and 15% in the AZA-untreated subgroup (p= 0.0007 at 7 years). Among the 34 patients, 44% were relapse-free at 1 year, but all had relapsed at 7 years (p = 0.0635). The overall resort to colectomy was 72%, while 19% of the patients remained colectomy-free. Sixty percent of a cohort of patients with steroid-refractory colitis responded to CsA and 60% of these responders retained the colon after 1 year. These figures fell to 35% at 7 years but improved to 60% on AZA. The overall need for colectomy remains high in these patients and toxicity must be monitored.

1 September 2002 in Digestive and Liver Disease
Verified
Journal Article
Closed access
GAGiovanni Clemente Actis
Giovanni Clemente Actis
MBM. Bruno
M. Bruno
MPM. Pinna-Pintor
M. Pinna-Pintor
FRF.P. Rossini
F.P. Rossini
MRM. Rizzetto
M. Rizzetto

12 April 2007 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
GAGiovanni Clemente Actis
Giovanni Clemente Actis
AOAlda Olivero
Alda Olivero
MLMarco Lagget
Marco Lagget
Rinaldo PellicanoRinaldo Pellicano
Rinaldo Pellicano
ASAntonina Smedile
Antonina Smedile
MRMario Rizzetto
Mario Rizzetto

1 October 2007 in Digestive and Liver Disease
Verified
Journal Article
Closed access
GAGiovanni Clemente Actis
Giovanni Clemente Actis
EBE. Bugianesi
E. Bugianesi
AOA. Ottobrelli
A. Ottobrelli
MRM. Rizzetto
M. Rizzetto

26 September 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RFRiccardo Fornaro
Riccardo Fornaro
GAGiovanni Clemente Actis
Giovanni Clemente Actis
Gian Paolo CavigliaGian Paolo Caviglia
Gian Paolo Caviglia
DPDemis Pitoni
Demis Pitoni
Davide Giuseppe RibaldoneDavide Giuseppe Ribaldone
Davide Giuseppe Ribaldone
Vagus nerve stimulation (VNS) is an accepted therapy for the treatment of refractory forms of epilepsy and depression. The brain–gut axis is increasingly being studied as a possible etiological factor of chronic inflammatory diseases, including inflammatory bowel diseases (IBD). A significant percentage of IBD patients lose response to treatments or experience side effects. In this perspective, VNS has shown the first efficacy data. The aim of this narrative review is to underline the biological plausibility of the use of VNS in patients affected by IBD, collect all clinical data in the literature, and hypothesize a target IBD population on which to focus the next clinical study.